Kamatani, Naoyuki <br/><br/>
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.  [electronic resource] 

 -  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases  Jun 2011 
 - S44-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1536-7355 
<br/><br/><label>Standard No.: </label>10.1097/RHU.0b013e31821d352f  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Allopurinol--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Febuxostat<br/>Female<br/>Follow-Up Studies<br/>Gout--blood<br/>Gout Suppressants--administration & dosage<br/>Humans<br/>Hyperuricemia--blood<br/>Japan<br/>Male<br/>Middle Aged<br/>Thiazoles--administration & dosage<br/>Time Factors<br/>Treatment Outcome<br/>Uric Acid--blood<br/>Xanthine Oxidase--antagonists & inhibitors